Health and Economic After-effects in Leicester Tuberculosis Cohort (HEAL-TB)
Quantifying the Short to Long-term Physical, Psychological, and Socioeconomic Consequences of Pulmonary and Extra-pulmonary Tuberculosis in Patients in Leicester: a Longitudinal Cohort Study.
HEAL-TB (Health and Economic After-effects in Leicester Tuberculosis cohort) is a prospective observational study examining recovery among adults with pulmonary and extrapulmonary tuberculosis (TB). The study aims to understand how physical health, mental health, quality of life, daily activity, work and economic wellbeing change during TB treatment and up to 12 months after treatment completion.
Participants may join the study at different stages, from diagnosis until six months after completing TB treatment, and will be followed prospectively until 12 months after treatment completion. The study uses questionnaires, lung function testing, the Incremental Shuttle Walk Test, wrist-worn activity monitoring and information collected during routine clinical care. No experimental treatment is provided and participants continue to receive their usual NHS care.
The study aims to describe recovery over time, compare recovery following pulmonary and extrapulmonary TB, and identify factors associated with persistent health problems or poorer recovery.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Descripción detallada
HEAL-TB is a single-centre prospective observational cohort study designed to characterise physical, psychological and socioeconomic recovery among adults with pulmonary and extrapulmonary tuberculosis. Participants may enter the cohort at different stages of the tuberculosis pathway, from diagnosis or early treatment until six months after treatment completion, and complete the assessments applicable from their point of enrolment onwards. Follow-up continues until 12 months after treatment completion.
The study combines patient-reported outcome measures with objective assessments of physical function and routinely collected clinical information. Outcomes include health-related quality of life, mental health, work productivity and socioeconomic wellbeing, perceived recovery, lung function, functional exercise capacity, physical activity, sedentary behaviour and sleep. Relevant clinical records, imaging reports and routine investigation results are also reviewed to provide information on disease severity, treatment, complications and recovery.
The study is primarily descriptive and exploratory. Recovery trajectories will be characterised over time, with exploratory comparisons between pulmonary and extrapulmonary tuberculosis. Clinical and disease-related characteristics will also be explored as potential predictors of persistent impairment and poorer recovery. The study is intended to improve understanding of recovery beyond treatment completion and inform future approaches to follow-up, rehabilitation and supportive care for people affected by tuberculosis.
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Jake Bodycot
- Número de teléfono: +447551792221
- Correo electrónico: jb1071@leicester.ac.uk
Ubicaciones de estudio
-
-
-
Leicester, Reino Unido, LE1 5WW
- University Hospitals of Leicester NHS Trust
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Adults with pulmonary or extrapulmonary tuberculosis receiving care or follow-up through University Hospitals of Leicester NHS Trust. Participants may enter the cohort at different stages of the tuberculosis treatment and recovery pathway, from diagnosis until six months after treatment completion. Participants will be recruited through the UHL clinical tuberculosis service across Leicester Royal Infirmary, Glenfield Hospital and Leicester General Hospital and followed prospectively from enrolment until the applicable final assessment at 12 months after treatment completion.
Descripción
Inclusion Criteria:
- Aged 16 years or above.
- Any sex/gender.
- Pulmonary or extrapulmonary tuberculosis, receiving or having recently completed tuberculosis treatment, with tuberculosis care or follow-up provided through University Hospitals of Leicester NHS Trust. The latest entry point into the cohort is six months after treatment completion.
- Willing and able to provide informed consent to participate in the study.
Exclusion Criteria:
- Expected to move out of the area or unable to attend follow-up visits.
- Prisoners or people under custodial care.
- Currently involved in research or recently involved in other research.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: COHORT
- Perspectivas temporales: PROSPECTIVE
Número de grupos/cohortes
Cohortes e Intervenciones
Grupo / CohorteGrupo / Cohorte |
|---|
|
Pulmonary Tuberculosis
Participants with pulmonary tuberculosis enrolled in the HEAL-TB observational cohort. Participants will undergo prospective follow-up and study assessments according to the HEAL-TB protocol. No intervention is assigned as part of the study. |
|
Extrapulmonary Tuberculosis
Participants with extrapulmonary tuberculosis enrolled in the HEAL-TB observational cohort. Participants will undergo prospective follow-up and study assessments according to the HEAL-TB protocol. No intervention is assigned as part of the study. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Health-related quality of life measured by EQ-5D-5L
Periodo de tiempo: Study entry and applicable follow-up assessments through 12 months after treatment completion
|
Health-related quality of life assessed using the EQ-5D-5L, including the EQ-5D-5L utility index and EQ Visual Analogue Scale (EQ VAS). Repeated measurements will be used to characterise changes in health-related quality of life during tuberculosis treatment and recovery. |
Study entry and applicable follow-up assessments through 12 months after treatment completion
|
|
Depressive symptoms measured by PHQ-9
Periodo de tiempo: Study entry and applicable follow-up assessments through 12 months after treatment completion
|
Depressive symptoms assessed using the Patient Health Questionnaire-9 (PHQ-9) total score. Repeated measurements will be used to characterise mental health trajectories during tuberculosis treatment and recovery. |
Study entry and applicable follow-up assessments through 12 months after treatment completion
|
|
Anxiety symptoms measured by GAD-7
Periodo de tiempo: Study entry and applicable follow-up assessments through 12 months after treatment completion
|
Anxiety symptoms assessed using the Generalized Anxiety Disorder-7 (GAD-7) total score. Repeated measurements will be used to characterise mental health trajectories during tuberculosis treatment and recovery. |
Study entry and applicable follow-up assessments through 12 months after treatment completion
|
|
Lung function measured by spirometry
Periodo de tiempo: Treatment completion, 6 months post-treatment and 12 months post-treatment, where visits are conducted face to face
|
Pre-bronchodilator spirometry including FEV1, FVC, FEV1/FVC ratio and percent predicted values. Repeated measurements will be used to characterise lung-function trajectories during recovery. |
Treatment completion, 6 months post-treatment and 12 months post-treatment, where visits are conducted face to face
|
|
Physical activity measured by wrist-worn activity monitor
Periodo de tiempo: Study entry and applicable follow-up assessments through 6 months after treatment completion
|
Wrist-worn activity monitoring over 7 days to measure daily physical activity, including steps per day and time spent sedentary and in different physical activity intensity levels. |
Study entry and applicable follow-up assessments through 6 months after treatment completion
|
|
Work productivity and activity impairment measured by WPAI
Periodo de tiempo: Study entry and applicable follow-up assessments through 12 months after treatment completion
|
Work Productivity and Activity Impairment questionnaire assessing work time missed, impairment while working, overall work impairment and activity impairment. Repeated measurements will characterise changes in work productivity and activity during treatment and recovery. |
Study entry and applicable follow-up assessments through 12 months after treatment completion
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Functional exercise capacity measured by Incremental Shuttle Walk Test
Periodo de tiempo: Treatment completion, 6 months post-treatment and 12 months post-treatment, where visits are conducted face to face
|
Functional exercise capacity assessed using the Incremental Shuttle Walk Test (ISWT), with total distance walked recorded in metres. |
Treatment completion, 6 months post-treatment and 12 months post-treatment, where visits are conducted face to face
|
|
Respiratory-specific quality of life measured by St George's Respiratory Questionnaire
Periodo de tiempo: Study entry and applicable follow-up assessments through 12 months after treatment completion
|
Respiratory health status assessed using the St George's Respiratory Questionnaire in participants with pulmonary tuberculosis only, measuring respiratory symptoms, activity limitation and psychosocial impacts. |
Study entry and applicable follow-up assessments through 12 months after treatment completion
|
|
Participant-reported recovery from tuberculosis
Periodo de tiempo: Study entry and applicable follow-up assessments through 12 months after treatment completion
|
Study-specific questions assessing whether participants consider themselves fully recovered from tuberculosis and how their perceived recovery has changed since the previous study visit. |
Study entry and applicable follow-up assessments through 12 months after treatment completion
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Investigadores
Investigadores
- Investigador principal: Manish Pareek, University of Leicester
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
Otros números de identificación del estudio
- 1107
- 223512/Z/21/Z (Otro número de subvención/financiamiento: Wellcome Trust)
- 365242 (Otro identificador: IRAS)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
There is currently no plan to make individual participant-level data publicly available. Study findings will be disseminated in aggregate form.
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .